Trials / Completed
CompletedNCT00525447
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-40 | 2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8. |
| DRUG | lenalidomide | Up to 25 mg daily of a 21-day cycle. |
| DRUG | dexamethasone | 40 mg administered weekly. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2010-01-01
- Completion
- 2010-02-01
- First posted
- 2007-09-05
- Last updated
- 2014-10-09
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00525447. Inclusion in this directory is not an endorsement.